https://www.appliedxl.com/news/huilun-hl-1186-postoperative-pain-trial-nct07709598 Biopharma News en 2026-07-16T15:45:28.543Z Shanghai Huilun opens second Phase 2/3 HL-1186 pain trial against oxycodone https://www.appliedxl.com/news/hengrui-hrs-6209-breast-cancer-delay-nct06555068 Biopharma News en 2026-07-16T15:36:02.747Z HengRui's HRS-6209 breast cancer trial pushes completion out two years https://www.appliedxl.com/news/takeda-elritercept-mds-enrollment-nct07319845 Biopharma News en 2026-07-16T15:35:45.491Z Takeda expands Japan trial of elritercept for lower-risk MDS anemia https://www.appliedxl.com/news/boehringer-bi-3034701-obesity-pk-study-nct07708493 Biopharma News en 2026-07-16T15:35:15.492Z Boehringer registers mass-balance study of obesity drug BI 3034701 https://www.appliedxl.com/news/innovent-ibi3035-phase1-recruiting-nct07591519 Biopharma News en 2026-07-16T15:35:09.142Z Innovent starts dosing IBI3035 in first-in-human trial against Novo, Lilly insulins https://www.appliedxl.com/news/fujian-akeylink-gst-hg131-hepatitis-b-phase2-nct07709520 Biopharma News en 2026-07-16T15:35:08.387Z Fujian Akeylink starts Phase 2 test of oral GST-HG131/141 in hepatitis B https://www.appliedxl.com/news/suncadia-hrs-2129-gout-trial-nct07706777 Biopharma News en 2026-07-16T15:34:59.972Z Suncadia registers Phase 2 trial testing HRS-2129 against gout flare pain https://www.appliedxl.com/news/radicle-science-menopause-fatigue-trial-nct07572578 Biopharma News en 2026-07-16T15:34:58.297Z Radicle Science's menopause fatigue trial moves to Active, not recruiting https://www.appliedxl.com/news/abbvie-emrelis-lung-cancer-delay-nct04928846 Biopharma News en 2026-07-16T15:25:20.090Z AbbVie pushes confirmatory lung cancer trial for Emrelis nine months https://www.appliedxl.com/news/lilly-baricitinib-sjia-enrollment-complete-nct04088396 Biopharma News en 2026-07-16T15:16:38.632Z Lilly's pediatric baricitinib trial closes enrollment after six delays https://www.appliedxl.com/news/daewoong-bersiporocin-ipf-readout-nct05389215 Biopharma News en 2026-07-16T15:16:10.005Z Daewoong's IPF trial closes enrollment as its 2026-10-13 readout nears https://www.appliedxl.com/news/suncadia-hrs-1780-hypertension-trial-nct07708441 Biopharma News en 2026-07-16T15:16:03.470Z Suncadia registers Phase 2/3 test of MRA HRS-1780 in resistant hypertension https://www.appliedxl.com/news/medilink-yl201-esophageal-cancer-phase3-nct07487896 Biopharma News en 2026-07-16T15:16:02.406Z MediLink's YL201 enters Phase 3 recruiting against chemo in esophageal cancer https://www.appliedxl.com/news/sichuan-baili-si-b036-phase1-enrollment-nct07678970 Biopharma News en 2026-07-16T15:15:19.150Z Sichuan Baili trims early Phase 1 trial of SI-B036 to 10 patients before dosing starts https://www.appliedxl.com/news/nexcella-nxc-201-al-amyloidosis-phase3-nct07709715 Biopharma News en 2026-07-16T15:14:59.060Z Nexcella moves NXC-201 into head-to-head Phase 3 test against daratumumab https://www.appliedxl.com/news/baili-bl-b01d1-esophageal-cancer-trial-nct07554456 Biopharma News en 2026-07-16T15:08:21.650Z Baili's BL-B01D1 opens enrollment in first-line esophageal cancer trial https://www.appliedxl.com/news/chia-tai-tianqing-tq05105-qt-study-nct07708272 Biopharma News en 2026-07-16T15:05:23.891Z Chia Tai Tianqing starts QT safety study for myelofibrosis drug TQ05105 https://www.appliedxl.com/news/suncadia-shr-a2009-solid-tumors-timing-nct05114759 Biopharma News en 2026-07-16T14:55:54.539Z Suzhou Suncadia pushes SHR-A2009 Phase 1 completion out three years to Dec 2026 https://www.appliedxl.com/news/suncadia-shr-a2009-solid-tumors-update-nct05114759 Biopharma News en 2026-07-16T14:55:25.622Z Suncadia's SHR-A2009 trial resumes reporting after status-registry gap https://www.appliedxl.com/news/mezzion-udenafil-2026-readout-nct03013751 Biopharma News en 2026-07-16T13:25:15.558Z Mezzion's udenafil cuts liver fibrosis marker in Fontan patients, not liver stiffness https://www.appliedxl.com/news/innocare-soficitinib-icp-332-2026-readout-nct07047612 Biopharma News en 2026-07-16T13:14:57.536Z InnoCare's soficitinib clears Phase II vitiligo endpoint versus placebo https://www.appliedxl.com/news/amt-b-v-elana-anastomotic-system-2026-readout-nct07005843 Biopharma News en 2026-07-16T12:54:48.378Z AMT Medical's sutureless bypass device hits 2.9% MACE at one year https://www.appliedxl.com/news/madrigal-resmetirom-2024-fda-decision-nct03900429 Biopharma News en 2026-07-16T12:25:45.761Z Madrigal's Rezdiffra won full FDA approval for MASH with fibrosis https://www.appliedxl.com/news/remix-rem-422-2026-data-nct06118086 Biopharma News en 2026-07-16T11:15:10.996Z Remix heads to AACR with a 43% ORR already in hand for REM-422 in ACC https://www.appliedxl.com/news/syntis-bio-synt-101-2026-readout-nct07307274 Biopharma News en 2026-07-16T11:16:39.343Z Syntis Bio's oral obesity pill shows early satiety-hormone signal in 32 healthy adults https://www.appliedxl.com/news/treprostinil-palmitil-inhalation-powder-tpip-pulmonary-nct05649748 Biopharma News en 2026-07-16T11:15:38.460Z Insmed's inhaled TPIP holds gains at 12 months, placebo group catches up https://www.appliedxl.com/news/merck-lipfendra-cholesterol-fda-approval-nct05952856 Biopharma News en 2026-07-16T12:00:42.646Z FDA approves Merck's oral PCSK9 inhibitor Lipfendra for high cholesterol https://www.appliedxl.com/news/disitamab-vedotin-bladder-cancer-pilot-data Biopharma News en 2026-07-16T19:44:42.382Z Small pilot links disitamab vedotin-toripalimab-radiotherapy to bladder preservation https://www.appliedxl.com/news/antioxidant-serum-uv-erythema-study Biopharma News en 2026-07-16T19:44:45.348Z Antioxidant serum cuts UV-induced erythema more than encapsulated vitamin C https://www.appliedxl.com/news/forward-fwd1802-pk-study-nct07476963 Biopharma News en 2026-07-16T14:55:06.264Z Forward Pharmaceuticals closes enrollment in FWD1802 food-effect PK study https://www.appliedxl.com/news/hengrui-shr-7367-solid-tumors-phase1-nct05740202 Biopharma News en 2026-07-16T15:05:12.559Z Hengrui completes Phase 1 SHR-7367 trial with enrollment cut to 22 from 182 https://www.appliedxl.com/news/lilly-mazdutide-alcohol-use-disorder-nct06817356 Biopharma News en 2026-07-16T15:25:45.015Z Lilly's mazdutide completes Phase 2 alcohol use disorder trial, data pending https://www.appliedxl.com/news/newsoara-hpp737-psoriasis-trial-nct07707141 Biopharma News en 2026-07-16T15:35:08.228Z Newsoara's HPP737 psoriasis trial surfaces in registry, results still unposted https://www.appliedxl.com/news/otsuka-jnt-517-pku-phase1-2-nct05781399 Biopharma News en 2026-07-16T15:25:15.332Z Otsuka's JNT-517 completes PKU Phase 1/2 study with enrollment reset to 163 https://www.appliedxl.com/news/innovent-teprotumumab-thyroid-eye-disease-trial-design-nct07265258 Biopharma News en 2026-07-16T00:05:17.048Z Innovent designs first head-to-head trial of IGF-1R drug versus steroids in TED https://www.appliedxl.com/news/rso-021-pleural-effusion-phase-1-nct05278975 Biopharma News en 2026-07-16T00:05:21.116Z RSO-021 controlled malignant pleural effusion in 67% of patients at 12 weeks https://www.appliedxl.com/news/copd-type2-inflammation-meta-analysis Biopharma News en 2026-07-16T00:14:44.366Z Meta-analysis: T2-targeted biologics cut COPD exacerbations 23% across 7 trials https://www.appliedxl.com/news/maia-biotechnology-inc-thio-6-thio-dg-2023-readout-c7e4cf Biopharma News en 2026-07-16T16:52:20.391Z MAIA reports 90.5% disease control in heavily pretreated lung cancer cohort